TRINETRA › Sectors › Healthcare
Krishna Institute of Medical Sciences Limited (KIMS) — share price, P/E and fundamentals
Krishna Institute of Medical Sciences Limited (NSE: KIMS) closed at ₹701.80 on 30 Oct 2026, -2.5% over one year, against a 52-week range of ₹575.80 – ₹858.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 3 Aug 2026) it reported revenue of ₹1,180 cr and net profit of ₹42 cr, a 3.5% net margin; revenue grew 35.3% and profit fell 51.1% year on year.
On four consecutive filed quarters its trailing P/E is 144.1; since 13 May 2025 its own P/E has ranged from 60.6 to 217.7 (median 79.3), and today's reading is higher than 87% of those 363 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 7.4%, ROCE 8.5%, debt-to-equity 1.44, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 11% of 63 sector peers; PBT margin higher than 10% of 63 sector peers; ROE higher than 14% of 63 sector peers.
Key figures
| Last close | ₹701.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -12.3% / +7.8% / -2.5% |
| 52-week low – high | ₹575.80 – ₹858.00 |
| Market capitalisation | ₹29,476 cr |
| Trailing P/E | 144.1 |
| Price / book | 13.12 |
| EV / EBITDA | 38.1 |
| Earnings yield | 0.7% |
| TTM EPS | ₹4.87 |
| TTM net profit | ₹205 cr |
| Quarter revenue | ₹1,180 cr |
| Quarter net profit | ₹42 cr |
| Net margin | 3.5% |
| Revenue growth (YoY) | +35.3% |
| Profit growth (YoY) | -51.1% |
| Return on equity | 7.4% |
| ROCE | 8.5% |
| Debt / equity | 1.44 |
| Current ratio | 0.76 |
| Free cash flow | ₹-917 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹33.2 cr |
Against Healthcare peers
| Metric | KIMS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 3.52 | 12.89 | 11 |
| PBT margin | 4.71 | 17.68 | 10 |
| ROE | 7.39 | 13.87 | 14 |
| ROCE | 8.53 | 17.26 | 14 |
| Debt / equity | 1.44 | 0.11 | 100 |
| Cash conversion | 2.11 | 1.25 | 87 |
| Trailing P/E | 144.13 | 43.07 | 97 |
| P/B | 13.12 | 5.88 | 84 |
Questions
What is the P/E ratio of Krishna Institute of Medical Sciences Limited?
Krishna Institute of Medical Sciences Limited's trailing P/E is 144.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 13 May 2025 its P/E has ranged 60.6–217.7.
What were Krishna Institute of Medical Sciences Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Krishna Institute of Medical Sciences Limited reported revenue of ₹1,180 cr and net profit of ₹42 cr (consolidated), filed with the exchange on 3 Aug 2026.
What is Krishna Institute of Medical Sciences Limited's ROE?
Return on equity is 7.4% based on the balance sheet dated 31 Mar 2026.
Does Krishna Institute of Medical Sciences Limited have debt?
Debt-to-equity is 1.44 on the balance sheet dated 31 Mar 2026.
What is KIMS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, KIMS traded between ₹575.80 and ₹858.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.